Skip to main content

Table 1 Patients´ characteristics and cancer type by site

From: Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America

  Argentina Brazil Chile Honduras Mexico Combined
  N = 156 N = 286 N = 154 N = 36 N = 151 N = 783
Sex (n = 783), % (n)
 Female 12% (19) 23% (67) 9% (14) 53% (19) 14% (21) 18% (140)
 Male 88% (137) 77% (219) 91% (140) 47% (17) 86% (130) 82% (643)
Age at cancer diagnosis (n = 783), median (IQR) 38 (33–45) 41 (35–48) 39 (33–49) 41 (30–48) 34 (29–42) 39 (32–47)
Years from HIV diagnosis to cancer diagnosis (n = 772), median (IQR) 1.79 (0.10–5.94) 3.97 (0.25–9.95) 1.88 (0.38–7.05) 1.60 (0.41–4.69) 0.45 (0.06–2.77) 1.67 (0.18–6.74)
Years from cART initiation to cancer diagnosis (n = 749), median (IQR) 0.040 (− 0.080–2.49) 0.53 (− 0.02–5.86) 0.33 (− 0.04–1.93) 0.53 (− 0.04–2.30) −0.010 (− 0.09–0.93) 0.19 (− 0.06–2.87)
Cancer diagnosis relative to cART initiation (n = 783), % (n)
 Cancer diagnosis after cART initiation 53% (83) 64% (183) 63% (97) 64% (23) 46% (69) 58% (455)
 Cancer diagnosis before/at cART initiation/Did not start cART 47% (73) 36% (103) 37% (57) 36% (13) 54% (82) 42% (328)
CD4 count (cells/μL) at cancer diagnosis (n = 537), median (IQR) 82 (14–276) 190 (54–425) 171 (56–388) 176 (90–382) 141 (45–300) 148 (44–364)
HIV-1 RNA at cancer diagnosis (log10) (n = 422), median (IQR) 4.4 (2.6–5.3) 3.2 (2.6–4.9) 2.6 (2.6–4.9) 2.6 (2.6–4.4) 4.6 (2.6–5.3) 3.9 (2.6 5.0)
HIV1-RNA status at cancer diagnosis (cut point = 400 copies/mL), % (n)
 Undetectable 31% (16) 49% (80) 49% (41) 67% (6) 38% (43) 44% (186)
 Detectable 69% (36) 51% (84) 51% (43) 33% (3) 62% (70) 56% (236)
Status at the end of follow-up (n = 783), % (n)
 Alive 81% (126) 61% (174) 67% (103) 61% (22) 84% (127) 70% (552)
 Dead 19% (30) 39% (112) 33% (51) 39% (14) 16% (24) 30% (231)
Follow-up (years) (n = 783), median (IQR) 2.20 (0.55–6.13) 2.30 (0.66–4.91) 3.69 (0.62–8.87) 1.06 (0.59–5.42) 3.33 (0.92–5.84) 2.51 (0.69–6.13)
Type of cancer (n = 783), % (n)
 AIDS-defining cancers 82% (128) 66% (188) 70% (108) 72% (26) 75% (114) 72% (564)
    Kaposi sarcoma 59% (92) 51% (147) 42% (65) 28% (10) 42% (64) 48% (378)
    Non-Hodgkin lymphoma 20% (31) 13% (38) 27% (41) 19% (7) 22% (33) 19% (150)
    Invasive cervical cancer 3% (5) 1% (3) 1% (2) 25% (9) 11% (17) 5% (36)
 Non-AIDS-defining cancers 18% (28) 34% (98) 30% (46) 28% (10) 25% (37) 28% (219)
    Anal 2% (3) 5% (15) 3% (4) 3% (1) 13% (19) 5% (42)
    Breast 1% (2) 5% (15) 1% (1) 6% (2) 0% (0) 3% (20)
    Colon 1% (2) 1% (3) 2% (3) 3% (1) 0% (0) 1% (9)
    Hodgkin lymphoma 2% (3) 1% (4) 6% (9) 0% (0) 5% (7) 3% (23)
    Lung 3% (4) 3% (8) 0% (0) 0% (0) 0% (0) 2% (12)
    Prostate 0% (0) 2% (5) 1% (1) 3% (1) 3% (5) 2% (12)
    Renal 1% (2) 2% (6) 0% (0) 0% (0) 0% (0) 1% (8)
    Skin 4% (7) 7% (20) 5% (7) 6% (2) 1% (1) 5% (37)
    Testicular 1% (1) 0% (0) 5% (7) 0% (0) 0% (0) 1% (8)
    Othera 3% (4) 8% (22) 9% (14) 8% (3) 3% (5) 6% (48)
  1. IQR interquartile range
  2. aOther: acute leukemia (2–2%), bladder cancer (2–2%), brain cancer (5–6%), cancer with unknown primary (3–3%), chronic leukemia (1–1%), esophageal cancer (3–3%), eye cancer (1–1%), gall bladder (1–1%), gastric cancer (7–8%), laryngeal cancer (3–3%), not otherwise specified leukemia (3–3%), liver cancer (1–1%), multiple myeloma (2–2%), oral cancer (4–4%), ovarian cancer (2–2%), pancreatic cancer (1–1%), penile cancer (1–1%), sinus cancer (1–1%), soft tissue sarcoma (1–1%), thyroid cancer (4–4%)